SynthesisBrain and behavior2025
Genome-Wide Meta-Analysis of Parkinson's Disease Associated Genetic Loci and Validation of Therapeutic Targets.
Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-Wide Meta-Analysis of Parkinson's Disease Associated Genetic Loci and Validation of Therapeutic Targets.Brain and behavior · 2025Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTo identify genetic loci associated with Parkinson's disease (PD) through a genome-wide meta-analysis, to screen for druggable genes significantly linked to PD risk, and evaluate their potential as therapeutic targets.
methodsData from DGIdb, GeneCards, and the Finan genomic resource were integrated to identify candidate therapeutic genes associated with PD. Genome-wide meta-analysis was conducted using GWAS data from the International Parkinson's Disease Genomics Consortium and FinnGen, involving 1,851,374 participants. Mendelian randomization (MR), colocalization analysis, and phenome wide association studies (PheWAS) were conducted to validate the associations between the identified genes and PD. Furthermore, knockout mouse models from the Mouse Genome Informatics were analyzed to validate PD-related phenotypes, and DSigDB was utilized to predict potential therapeutic compounds.
resultsWe identified several therapeutic genes significantly associated with PD risk. Colocalization analysis suggested shared causal genetic variants between these genes and PD. PheWAS further revealed that GCLC and GFPT1 exhibit limited pleiotropic effects across other traits. Eight potential compounds were identified through DSigDB predictions.
conclusionThrough genome-wide meta-analysis, MR, colocalization, and PheWAS, we identified genetic loci associated with PD and assessed GCLC and GFPT1 as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.